Skip to main content
Equibles
ALT logo

ALT · Altimmune, Inc. · Metrics

Track ALT — free

Use ALT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.30 +0.07 (+3.14%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$441.56M
Shares
194.52M
Volume · Oct 20 2.29M Avg daily vol (3M) 4.25M

ALT metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.30
Market cap
$441.56M

Price action

20 metrics
Price change (1W)
-12.9%
Price change (30D)
-31.8%
Price change (3M)
-20.6%
Price change (6M)
-37.4%
Price change (YTD)
-38.2%
Price change (1Y)
-41.8%
Trailing year
Price change (5Y)
-82.0%
52-week high
$6.18
52-week low
$2.20
Change from 52-week high
-63.9%
Change from 52-week low
+1.4%
Annualized volatility
69.4%
Annualized volatility (3M)
48.7%
Beta
1.6
RSI (14D)
22.6
Price vs SMA 50
-25.2%
Price vs SMA 200
-33.8%
Avg volume (3M)
4.25M
Relative volume
0.6
Average dollar volume
$12.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
194.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4,651.6×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
10,485.0×
reciprocal yield 0.0%
P / book
0.9
reciprocal yield 110.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
-230,461.0%
Trailing 12 months
Net margin
-214,861.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$100.22M
Net income (TTM)
−$91.76M
Trailing 12 months
Diluted EPS (TTM)
$-0.77
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.03

Growth

11 metrics
Revenue growth YoY
+420.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$41,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+127.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-65.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-19.4%
Return on assets
-17.4%
Debt / equity
0.1
Current ratio
26.8
EBITDA (TTM)
−$87.05M
Free cash flow (TTM)
—
Quick ratio
26.8
Interest coverage
-28.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$291.54M
Latest balance sheet
Cash & equivalents
$63.01M
Total assets
$527.21M
Total debt
$34.74M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$76.51M
Capital expenditures (TTM)
$54,000
R&D (TTM)
$68.22M
SG&A (TTM)
—
Stock compensation (TTM)
$14.66M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
211
13F filer change QoQ
+37
Institutional ownership
78.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
22.7%
Private-fund adviser ownership
21.9%
Active holders' share change QoQ
+185.2%
Holder tenure
7.6
Price vs estimated holder cost
-17.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.0%

Short interest

3 metrics
Short interest
23.7%
Latest settlement · 10.5 days to cover
Days to cover
10.5d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
$44,250
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1326190 CUSIP 02155H200 13F (30d) 21 filings 21 filers Visit website Investor relations